Features Screener Stocks Charts
Sign In Sign Up

Sequent Scientific Cash Flow Statement

NSE:SEQUENT | PHARMACEUTICALS

Showing 2 of 10 years of data. Sign up free for 3 years, or upgrade for full access.

View Plans

Cash Flow Insights

Cash Conversion

1.88x

SEQUENT's operating cash flow exceeded net income in FY 2025, indicating earnings are backed by actual cash generation.

Free Cash Flow

₹442.75M

SEQUENT's free cash flow was ₹442.75M in FY 2025, up 20,984.4% from FY 2024.

CapEx Intensity

46.9%

Capital expenditure was 46.9% of operating cash flow in FY 2025 for SEQUENT, a moderate level of reinvestment.

2-year SEQUENT cash flow snapshot

Hover the chart icon for YoY change.

FY 2024 - FY 2025
Item Chart 2024 2025
Net Income -546.46M 443.06M
Cash flow Operating Activities 305.95M 833.62M
Investments in PPE -308.07M -390.87M
Cash flow Investing Activities -59.20M -247.78M
Dividend Paid 0 0
Cash flow Financing Activities -14.39M -607.34M
Cash at beginning of period 415.74M 648.10M
Cash at end of period 648.10M 626.60M
Free Cash Flow -2.12M 442.75M

Values are shown in millions (M) and billions (B). All amounts are in Indian Rupees (₹).

Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2025